All‐cause mortality · people undergoing laparotomy for penetrating abdominal trauma
It is very uncertain whether gram‐positive and gram‐negative coverage changes mortality compared with gram‐negative and anaerobic coverage (very low certainty).
1 finding from 1 review
Intra‐abdominal infection · people undergoing laparotomy for penetrating abdominal trauma
It is very uncertain whether gram‐positive and gram‐negative coverage changes intra‐abdominal infection compared with gram‐negative and anaerobic coverage (very low certainty).
1 finding from 1 review
Abdominal surgical site infection · people undergoing laparotomy for penetrating abdominal trauma
It is very uncertain whether anaerobic coverage only changes abdominal surgical site infection compared with gram‐positive, gram‐negative, and anaerobic coverage (very low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing laparotomy for penetrating abdominal trauma
1 finding from 1 review
Intra‐abdominal infection · people undergoing laparotomy for penetrating abdominal trauma
It is very uncertain whether anaerobic coverage only changes intra‐abdominal infection compared with gram‐positive, gram‐negative, and anaerobic coverage (very low certainty).
1 finding from 1 review
Intervention not reported
All cause mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of severe infections (Grade III or IV) · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in incidence of severe infections (Grade III or IV) (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in adverse events Toxic deaths (low certainty).
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
It is very uncertain whether the intervention changes incidence of febrile neutropenia (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of severe infections · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All cause mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found